Nyrada Received $1M R&D Tax Rebate, Funded to Sustain Operations Through 2021
- July 31, 2020 11:24 AM AEST
- Team Kalkine Media
Nyrada’s Brain Injury Drug Candidates Delivered via Preferred Administration Route
- July 21, 2020 11:41 AM AEST
- Team Kalkine Media
Nyrada’s Lead Programs Advancing Well, Minimal Impact from COVID-19
- June 26, 2020 02:42 PM AEST
- Team Kalkine Media
Nyrada Developing New Therapies for Cardiovascular Disease and Neurological Disorders
- May 05, 2020 12:11 PM AEST
- Team Kalkine Media
Australian pre-clinical pharmaceutical company, Nyrada Inc. (ASX: NYR) is advancing well with its drug development objectives, to cater to the large, underserved therapeutic needs of its targeted patient groups. The newly-listed dr...
Nyrada Quarterly Update Highlights Key Program Developments, Strong Cash Position
- April 20, 2020 04:56 PM AEST
- Team Kalkine Media
With an expected healthy cash runway until the end of 2021, Australian pharmaceutical company Nyrada Inc. (ASX: NYR) appears to be progressing well in its drug discovery and development program of its two lead programs in cholesterol-lowering and bra...
Lens through Nyrada’s Neuroprotection Program: Treatment for TBI & Stroke
- April 07, 2020 11:27 AM AEST
- Team Kalkine Media
Australian drug discovery and development company Nyrada Inc. (ASX: NYR) which listed in January, reports solid progress in advancing its two lead R&D programs, one a treatment for brain injury and the other a novel cholesterol loweri...
Recently Listed Nyrada is Improving Lives and Providing Hope Through Innovation in Drug Development
- March 04, 2020 02:43 PM AEDT
- Team Kalkine Media
US-registered Nyrada Inc is a biopharmaceutical company focussed on discovery and early phase drug development. It listed on the Australian Securities Exchange on 16 January 2020 (ASX: NYR) and the IPO offer was fully subscribed, raising A$8.5 millio...
